BPET
The Next-Generation of Small, Cost-Effective and Mobile Brain Scanner for an Early Detection of Alzheimer’s Disease
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0BPET project word cloud
Explore the words cloud of the BPET project. It provides you a very rough idea of what is the project "BPET" about.
Project "BPET" data sheet
The following table provides information about the project.
| Coordinator |
POSITRIGO AG
Organization address contact info |
| Coordinator Country | Switzerland [CH] |
| Project website | https://www.positrigo.com/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-02-01 to 2019-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | POSITRIGO AG | CH (ZURICH) | coordinator | 50˙000.00 |
Map
Project objective
Alzheimer’s (AD) is a global epidemic with 50 M people suffering it and 76 M expected by 2030 (related costs near $1 Tri in 2018). To diminish its burden, an early detection is crucial, specially when modifying treatments become available. The most accurate method to measure AD hallmarks is positron emission tomography (PET), but current PET scanners are multi-modal, whole-body, room-filling, expensive to acquire (€1-5 M) and not commonly used. Thus, there is still a need for more efficient diagnostic tools to detect AD at an early stage to adopt the best live-lasting treatment. Positrigo is a Swiss start-up, founded with the goal of provide an efficient PET tool for the early diagnosis of neurodegenerative diseases. Our technology has enabled us to develop a first prototype of BPET which has been preliminary tested in the laboratory with high performance. BPET is a dedicated mobile brain scanner with the size of a drying hood, 10x less capital (€400 k instead of millions) and 5x less operational expenses than current scanners. It will greatly improve early diagnosis of AD, facilitate its treatment follow-up and contribute to accelerate drug development programs, with a 10x increase in scanning capacity. BPET can be sold to hospitals and clinical research organizations, tailored to the needs of patients and doctors, and it can enable new case uses of brain PET (e.g many scanners used in parallel, wider populations, in larger cohort research studies). Diverse hospitals have shown their interest in BPET and their support for its complete development for its potential applications and impact. To launch BPET in the healthcare market we need its CE marking, clinical validation and industrial adaptation, so a total of €2.5M for phase 2 will be requested. BPET project will pave the way for our company to be established as an innovative alternative in scanner-based diagnosis, boosting our company to grow and reach around €30 M profits and a ROI of 7.4 after 5 years.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BPET" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BPET" are provided by the European Opendata Portal: CORDIS opendata.